AstraZeneca said on Friday it has agreed to a research deal with Chinese drugmaker CSPC Pharmaceuticals worth up to $5.22 billion to focus on AI-enabled initiatives.
(Reporting by Pushkala Aripaka in Bengaluru)
SpaceX on Thursday priced the biggest-ever U.S. initial public offering at $135 per share, making Elon Musk’s rocket and spacecraft...
Weak cash distributions to investors in recent years are making it harder for private equity firms to raise new money,...
The World Bank on Thursday cut its global growth forecast for 2026 to 2.5% due to the war in the...
The European Central Bank raised interest rates for the first time in nearly three years on Thursday in the hope...
Deep in an underground bunker, where walls of screens stream live data from across the battlefield, the commander of Ukraine's...
Germany's construction sector has not yet emerged from its downturn, with a tentative recovery being hit by a new geopolitical...
© 2024 SEMG.
